Characteristics of patients treated with FAI or FM
Characteristics . | FAI . | FM . | P . |
|---|---|---|---|
| No. patients | 32 | 62 | |
| Average age, y (range) | 61 (27-74) | 54 (22-75) | .001 |
| No. female (%)/no. male (%) | 18 (56)/14 (44) | 29 (47)/33 (53) | .514 |
| Average mos. from diagnosis to treatment (range) | 10 (1.1-48.6) | 12 (0.9-173.6) | .662 |
| No. prior therapies (range) | 2 (0-4) | 2 (0-8) | .399 |
| Diagnosis, no. (%) | |||
| AML | 26 (81) | 42 (68) | |
| MDS | 6 (19) | 20 (32) | .253 |
| Stage at transplantation, no. (%) | |||
| Remission | 14 (44) | 10 (16) | .006 |
| Not in remission | 18 (56) | 52 (84) | |
| First remission at transplantation, no. (%) | 9 (28) | 2 (3) | .0008 |
| Donor type, no. (%) | |||
| Matched sibling | 26 (81) | 25 (40) | |
| Mismatched related | 6 (19) | 8 (13) | <.001 |
| Matched unrelated | 0 (0) | 29 (47) | |
| Stem cell source, no. (%) | |||
| Bone marrow | 27 (84) | 26 (42) | <.001 |
| Peripheral blood | 5 (16) | 36 (58) |
Characteristics . | FAI . | FM . | P . |
|---|---|---|---|
| No. patients | 32 | 62 | |
| Average age, y (range) | 61 (27-74) | 54 (22-75) | .001 |
| No. female (%)/no. male (%) | 18 (56)/14 (44) | 29 (47)/33 (53) | .514 |
| Average mos. from diagnosis to treatment (range) | 10 (1.1-48.6) | 12 (0.9-173.6) | .662 |
| No. prior therapies (range) | 2 (0-4) | 2 (0-8) | .399 |
| Diagnosis, no. (%) | |||
| AML | 26 (81) | 42 (68) | |
| MDS | 6 (19) | 20 (32) | .253 |
| Stage at transplantation, no. (%) | |||
| Remission | 14 (44) | 10 (16) | .006 |
| Not in remission | 18 (56) | 52 (84) | |
| First remission at transplantation, no. (%) | 9 (28) | 2 (3) | .0008 |
| Donor type, no. (%) | |||
| Matched sibling | 26 (81) | 25 (40) | |
| Mismatched related | 6 (19) | 8 (13) | <.001 |
| Matched unrelated | 0 (0) | 29 (47) | |
| Stem cell source, no. (%) | |||
| Bone marrow | 27 (84) | 26 (42) | <.001 |
| Peripheral blood | 5 (16) | 36 (58) |
FAI indicates fludarabine, araC, and idarubicin; FM, fludarabine and melphalan.